Nigeria’s pharmaceutical manufacturers have delivered their strongest earnings in at least a decade, signalling a sharp reversal from years of margin squeeze buoyed by currency volatility and steep import dependence.
Drug manufacturers listed on the Nigerian Exchange Limited more than doubled their full-year incomes in 2025, rising from N6.5 billion in 2024 to N14.8 billion, thanks to the stability of the naira and tax waivers that helped sustain growth amid still weakened purchasing power.
Neimeth International Pharmaceuticals delivered
